Skip to main content
Nxera Pharma Co., Ltd. logo

Nxera Pharma Co., Ltd. — Investor Relations & Filings

Ticker · 4565 ISIN · JP3431300007 LEI · 2138004M62BFNJMR2Z82 T Manufacturing
Open in API
Filings indexed 113 across all filing types
Latest filing 2026-05-19 Share Issue/Capital Cha…
Country JP Japan
Listing T 4565

About Nxera Pharma Co., Ltd.

https://www.nxera.life/

Nxera Pharma Co., Ltd. (formerly Sosei Group Corp.) is a technology-driven biopharmaceutical company focused on the discovery and early development of novel medicines. The company utilizes its proprietary StaR® technology and world-leading expertise in G protein-coupled receptor (GPCR) structure-based drug design (SBDD) to create therapeutics for diseases with high unmet medical needs. By integrating advanced science and technology, Nxera Pharma develops its internal pipeline and collaborates with partners to accelerate the creation of life-changing treatments for patients worldwide. Its mission is to invest in science and technology to accelerate the development of these medicines.

Recent filings

Filing Released Lang Actions
RSU制度に基づく新株式発行に関する一部失権（発行株式数減少等）のお知らせ
Share Issue/Capital Change Classification · 85% confidence The document is an official notice from Nexera Pharma regarding changes to the number of shares issued under its RSU (Restricted Stock Unit) equity compensation plans, detailing share counts, issue prices, and reasons for partial lapses. This constitutes an announcement of new share issuance and associated capital changes. Therefore, it fits the category for Share Issue/Capital Change.
2026-05-19 Japanese
GPCR標的プログラムの導出契約の進捗およびシリーズA資金調達への一部出資に関するお知らせ
Capital/Financing Update Classification · 92% confidence The document is a public notice (“お知らせ”) from the IR department announcing the company’s participation in a Series A financing round for a venture spun out around its GPCR targeting program. It details the capital commitment, licensing terms, equity stake, and strategic governance (director appointment) in the context of a financing activity. This falls squarely under “Capital/Financing Update” as it relates to the company’s fundraising and investment activities, not an earnings release, regulatory filing, or annual/interim report.
2026-05-11 Japanese
2026年12月期第１四半期決算短信〔ＩＦＲＳ〕(連結)
Regulatory Filings
2026-05-01 Japanese
2026年12月期第1四半期（1月-3月）ビジネスハイライトおよび連結業績について
Regulatory Filings
2026-05-01 Japanese
アッヴィ社との神経疾患を対象とした創薬提携において10百万米ドルのマイルストンを受領
Regulatory Filings
2026-04-20 Japanese
訂正有価証券届出書（参照方式）
Share Issue/Capital Change Classification · 95% confidence The document is a full securities registration statement (有価証券届出書) detailing a new share issuance under an RSU plan—covering issue size, conditions, pricing, and legal disclosures. It is not an annual report, earnings release, or management discussion, but a prospectus for capital increase via share issuance. This fits the “Share Issue/Capital Change” category (SHA).
2026-04-15 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.